Vericel Corporation Aktie News

Der Gesamtumsatz stieg um 22 % auf 77,5 Mio. USD, mit einem Umsatzwachstum von MACI von 23 % Nettogewinn von 2,2 Mio. USD und Free Cash Flow von 14,3 Mio. USD Jahresumsatzprognose für 2026 auf 330 bis 340 Mio. USD angehoben Vorstand genehmigt Aktienrückkaufprogramm in Höhe von 200 Mio. USD Telefonkonferenz heute um 8:30 Uhr Eastern Time BURLINGTON, Mass., 30. Juli 2026 (GLOBE NEWSWIRE) -- Veric...

Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results an...

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within t...